Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins

Area of Science:

• Molecular Biology
• Cancer Genetics
• Drug Discovery

Background:

• Splicing of precursor messenger RNA (pre-mRNA) is essential for gene expression, with the spliceosome complex playing a central role.
• Aberrant splicing mechanisms, particularly mutations in spliceosomal proteins, are increasingly recognized as drivers of cancer pathogenesis.
• These spliceosomal mutations are prevalent in myeloid and lymphoid leukemias, highlighting their significance in cancer development.

Purpose of the Study:

• To review the mechanisms by which altered splicing contributes to cancer.
• To discuss the therapeutic potential of targeting spliceosomes in cancer treatment.
• To highlight recent advances and ongoing clinical trials in spliceosome modulation for cancer therapy.

Main Methods:

• Review of current literature on spliceosome function and its role in cancer.
• Analysis of studies investigating pharmacologic modulation of splicing.
• Examination of preclinical and clinical data on spliceosome-targeting therapies.

Main Results:

• Mutations in spliceosomal proteins are common in leukemias and can be therapeutically targeted.
• Pharmacologic modulation of splicing can be selectively lethal to cancer cells with spliceosomal mutations.
• Targeting the SF3B complex is a promising strategy, with a clinical trial initiated for a novel oral compound.

Conclusions:

• Understanding the mechanistic basis of altered spliceosomal function in cancer is crucial.
• Spliceosome modulatory compounds show potential as a therapeutic strategy for various cancers.
• Further preclinical studies and well-designed clinical trials are needed to evaluate these novel therapies.